Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report

The development of therapeutic agents targeting products of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has improved survival in patients with non-small-cell lung cancer. EGFR and ALK mutations are generally regarded as mutually exclusive...

Full description

Saved in:
Bibliographic Details
Published inDiagnostics (Basel) Vol. 13; no. 19; p. 3112
Main Authors Park, Sonya Youngju, Yoon, Hyukjin, Han, Eun Ji, Yoo, Ie Ryung
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2023
MDPI
Subjects
ALK
Cancer
Cancer therapies
Care and treatment
Case reports
Conflicts of interest
Crizotinib
EGFR
Epidermal growth factor
FDG PET/CT
Gene mutations
Genetic aspects
Health aspects
Interesting Images
Kinases
Lung cancer
Lung cancer, Non-small cell
Metastasis
Mutation
Non-Hodgkin's lymphomas
non-small-cell lung cancer
Patients
Phosphorylation
Review boards
Tumors
Online AccessGet full text

Cover

More Information
Summary:The development of therapeutic agents targeting products of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has improved survival in patients with non-small-cell lung cancer. EGFR and ALK mutations are generally regarded as mutually exclusive, and the presence of one in lieu of another influences the response to targeted therapy. We herein present an interesting case following the course of progression of a patient with synchronous lung cancers with a discordant mutation profile. The importance of this modality in the follow-up of lung cancer patients is illustrated, and the therapeutic implications of coexisting oncogenic drivers are briefly discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics13193112